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months. CONCLUSION: Our findings showed that pseudoprogression can 
occur early in the treatment course in CMMRD patients. Identification of this 
entity is important for appropriate clinical management.
RARE-16. SEVEN CASES OF RETINOBLASTOMA WITH CNS 
INVOLVEMENTS
Chikako Kiyotani, Masahiro Sugawa, Yukihiro Matsukawa, 
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Yoshiyuki Tsutsumi, Hiroshi Fuji, Kenichi Usami, Hideki Ogiwara, 
Keita Terashima, and Kimikazu Matsumoto; National Center for Child 
Health and Development, Tokyo, Japan
Treatment strategy for trilateral retinoblastoma (TRb: very rare RB with 
brain tumor) or retinoblastoma with central nervous system (CNS) involve-
ment is not established yet. We retrospectively reviewed our seven cases of 
these rare almost fatal tumors. Their ages at diagnosis are 0y3m-1y10m 
(median 1y3m) (Male 4, Female 3). Only one had RB family history. Their 
affected eyes were bilateral 3, unilateral 3 and no 1. Their CNS involve-
ments were suprasellar tumor 4, pineal tumor 1 and cerebrospinal fluid 
(CSF) cytology positive 2. Three of the suprasellar tumor patients had spinal 
metastasis. Four of the seven patients were TRb and one were genetically 
classified suprasellar retinoblastoma. All of them were treated with chemo-
therapy and four received high-dose chemotherapy. Three brain tumors of 
four TRb almost disappeared with chemotherapy. Two of them also received 
radiotherapy but relapsed. Although one radiation-free long-term TRb sur-
vivor developed secondary osteosarcoma, he got remission again and live 
5 more years. One CSF positive Rb patient with chiasm invasion died of 
disease 11 months later. The other patient had no chiasm invasion nor CSF 
involvement at diagnosis, but his CSF cytology turned to positive after his 
second cycle of chemotherapy. He got remission with radiotherapy and high-
dose chemotherapy, and alive without disease for 4 years. 2-year RFS and 
2-year OS of all patients were 40% and 60%. Although our TRb patients 
responded to chemotherapy, it was difficult to avoid radiotherapy except 
one. Data accumulation is necessary for better treatment of these cancer-
predisposed patients.
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BACKGROUND: Constitutional mismatch repair deficiency syndrome 
(CMMRD) is a severe cancer predisposition syndrome resulting in early 
onset central nervous system (CNS) and other cancers. International guide-
lines for surveillance exist but no study has systematically evaluated the ef-
ficacy of this protocol. METHODS: We surveyed all confirmed CMMRD 
patients in the International Replication Repair Deficiency Consortium. 
A surveillance protocol consisting of frequent biochemical, endoscopic and 
imaging (CNS and total body MRI) studies were employed. Survival ana-
lyses and efficacy of each method were assessed.  RESULTS: Surveillance 
data were collected from 105 CMMRD individuals from 41 countries. 
Of the 193 malignant tumors, CNS malignancies were the most common 
(44%). The surveillance protocol uncovered 49 asymptomatic tumors 
including 16 glioblastomas and medulloblastomas. Five-year overall sur-
vival was 89% for tumors discovered by surveillance, and 61% for symp-
tomatic tumors (p<0.004). Similarly, 5-year survival was 82+/-11% and 
24+/-6% for surveillance and non-surveillance of brain tumors (p=0.005). 
Yearly total body and q6 month brain MRI detected asymptomatic cancers 
in all but 3 symptomatic CNS gliomas. These were tumors uncovered when 
time between scans was >6 months as per protocol. Finally, of the low grade 
tumors identified asymptomatically, 5 were low grade gliomas. All of the low 
grade gliomas, which were not resected transformed to high grade tumors at 
a median of 1.6 ± 0.9 years. CONCLUSION: These data support a survival 
benefit in CMMRD patients undergoing a surveillance protocol. Adherence 
to protocol and resection of lower grade lesions may improve survival for 
patients with CNS tumors.
RARE-18. GENETIC EVALUATION IN PATIENTS WITH CHOROID 
PLEXUS TUMORS
Milena Oliveira, Nasjla Silva, Andrea Cappellano, Daniela Almeida, 
Sergio Cavalheiro, Patrícia Dastoli, Frederico Silva, and Fernanda Lima; 
IOP/GRAACC/UNIFESP, São Paulo, São Paulo, Brazil
INTRODUCTION: Choroid plexus tumors (CPT) are rare 
intraventricular neoplasms of epithelial origin. They usually occur in the 2nd 
year of life, corresponding to 0.4–0.6% of intracranial tumors in this age 
group. They are sub classified, according to WHO 2016, in choroid plexus 
carcinoma (CPC), atypical choroid plexus papilloma (ACPP) and choroid 
plexus papilloma (CPP). Li-Fraumeni syndrome (LFS) is present in 50% of 
patients with CPC. In Brazil, the TP53 p.R337H mutation affects 0.3% of 
the population in the South/Southeast. OBJECTIVE: Evaluate the incidence 
of genetic mutations in patients with choroid plexus tumors and therefore 
the importance of genetic evaluation.  PATIENTS AND METHODS: Be-
tween 1992–2019, 38 patients were diagnosed with CPT in our institution, 
23 with CPC. From 2012, 21 patients were referred for genetic evaluation, 
16 of which had CPC (2 had previously CPP). Positive family history for 
neoplasms was present in 87.5%; 37.5% compatible with LFS, 50% of 
them with mutations. All the patients with positive, but unspecific, family 
history of neoplasms, had pathogenic mutation. The molecular investiga-
tion of the TP53 gene in patients with CPC was performed and positive 
in 56.2%: R337H (5 patients), R110C, R158H, H179R, R196* (1 patient 
each). Of those with R337H, p53 protein immunohistochemistry resulted in 
90–100% positivity. One of the patients with CPP that evolved to CCP had 
the H179R mutation. Clinical course was similar among them, and with 
those without mutations. CONCLUSION: These results confirm the need 
for genetic evaluation in patients with choroid plexus tumors for adequate 
therapeutic management and long-term follow-up.
RARE-19. PEDIATRIC HIGH GRADE GLIOMA WITH DNA REPAIR 
PATHWAY ABERRATIONS, CLINICAL CHARACTERISTICS AND 
OUTCOME
Muhammad Baig, David McCall, Tyler Moss, David Sandberg, 
Gregory Fuller, Susan McGovern, Arnold Paulino, Amer Najjar, 
Joya Chandra, Soumen Khatua, and Wafik Zaky; MD Anderson Cancer 
Center, Houston, TX, USA
DNA mismatch repair machinery is an integral part of the human genome 
and its defect has been involved in tumorigenesis and treatment resistance. 
Heterozygous monoallelic germline loss of function in MLH-1, MSH-2, 
MSH-6 or PMS-2 is involved in Lynch syndrome, whereas biallelic muta-
tions cause constitutional mismatch repair deficiency (CMMRD) which is 
associated with hematologic malignancies and glioblastoma. We report here 
the clinical characterization and molecular analyses of 7 patients who pre-
sented with gliomas and MMR machinery aberrations. Two patients had 
a clinical diagnosis of NF-1 with dermatologic stigmata, of whom one pa-
tient has CMMRD and the other has Lynch syndrome. Two patients had a 
known family history of Lynch syndrome upon their diagnosis of glioma. 
Three patients with high-grade glioma and negative family history, 2 had 
germline mutations in MMR genes, and one had numerous mutations 
including MMR genes with microsatellite instability. Patients were initially 
treated with chemotherapy and radiation for high-grade gliomas (HGG); 
5/7 had progression. Median time to progression was 12  months (range: 
5–52), and median time from progression to death was 7 months (range: 
2–25). One patient had low-grade glioma initially but progressed to HGG 
and is currently on therapy. Another patient treated with temozolomide and 
radiation is currently receiving maintenance therapy without any disease 
recurrence. Although the literature data on brain tumors with MMR de-
ficiency is limited, these consistently show that MMRD-associated gliomas 
are treatment-resistant and have a dismal outcome. Collaborative efforts are 
needed to better understand this subgroup of pediatric HGG and to define 
optimal treatment strategy.
RARE-20. MALIGNANT PERIPHERAL NERVE SHEATH TUMOR OF 
A CRANIAL NERVE IN AN INFANT WITH NEUROCUTANEOUS 
MELANOSIS
Lacey Carter, Naina Gross, Rene McNall-Knapp,and Jo Elle Peterson; 
University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
At one month of age, a female presented with a giant congenital nevus 
along lower back and thighs and hydrocephalus. A  ventriculoperitoneal 
shunt was placed. An MRI was done at six months, initially reported as 
normal. At eleven months of age, five months after original MRI, patient 
presented with dysconjugate gaze and lethargy. MRI showed new 3.8 x 3.7 x 
3.4 cm right cerebellopontine angle mass extending into Meckel’s cave and 
foramen ovale along with leptomeningeal disease extending from the mass 
along the entire length of the spinal cord. Retrospective review of prior MRI 
revealed subtle leptomeningeal enhancement concerning for neurocutaneous 
melanosis (NCM). Given the leptomeningeal disease, family elected for open 
biopsy and debulking of lesion instead of aggressive resection. Histologically, 
the mass showed hypercellular spindle cell neoplasm with mitotic activity 
and necrosis mixed with remnants of normal cranial nerve. GFAP was nega-
tive, excluding a glioma. HMB-45, MITF, panmelanoma, and Melan-A 
were negative, excluding melanoma. A negative myogenin stain ruled out 
ectomesenchymoma. S-100 protein and SOX-10 positivity with variable loss 
of staining for trimethylation of histone H3 K27 were indicative of ma-
lignant peripheral nerve sheath tumor (MPNST). Given the course of the 
mass, trigeminal nerve MPNST was presumed. Given the poor prognosis 
of intracranial MPNST and NCM, family elected to forgo treatment and 
was discharged with hospice. She died 25 days after surgery. Cranial nerve 
MPNST is rare. MPNST in patients with NCM has not previously been re-
ported to our knowledge.
RARE-21. CANCER SPECTRUM IN GERMLINE SUFU MUTATION 
CARRIERS: A COLLABORATIVE PROJECT OF THE SIOPE HOST 
GENOME WORKING GROUP
Léa Guerrini-Rousseau1, Sebastian Waszak2, Franck Bourdeaut3, 
Olivier Delattre3, Nicola Dikow4, Christelle Dufour1, Amar Gajjar5, 
Jacques Grill1, Steffen Hirsch4, Saskia Hopman6, David Jones7, 
Majoline Jongmans6, Andrey Korshunov4, Christian Kratz8,  
Lucie Lafay-Cousin9, Julien Masliah3, Till Milde10, 
Paul Northcott5, Kristian Pajtler7, Stefan Pfister7, Stéphanie Puget11, 
Marie Agnès Rame Collonge12, Giles Robinson13, Eric Sariban14, 
Nicolas Sevenet15, Miriam Smith16, Dominik Sturm10, Hélène Zattara17, 
Pascale Varlet18, Gareth Evans19, and Laurence Brugières1; 1Gustave 
Roussy, Villejuif, France, 2EMBL, Heidelberg, Germany, 3Institut Curie, 
Paris, France, 4Medicine University, Heidelberg, Germany, 5St. Jude, 
Memphis, TN, USA, 6UMC, Utrecht, Netherlands, 7KiTZ, Heidelberg, 
Germany, 8MH, Hannovre, Germany, 9Alberta Children Hospital, Calgary, 
AB, Canada, 10DKFZ, Heidelberg, Germany, 11APHP Necker, Paris, France, 
12CHU, Besançon, France, 13St. Jude, Memphis, TN, USA, 14Hôpital 
Universitaire des Enfants Reine Fabiola, Bruxelles, Belgium, 15Institut 
Bergonié, Bordeaux, France, 16University, Manchester, United Kingdom, 
17APHM, Marseille, France, 18St. Anne Hospital, Paris, France, 19St. Mary’s 
Hospital, Manchester, United Kingdom
BACKGROUND: Little is known about cancer risk associated with 
pathogenic germline SUFU variants.  METHODS: Data of all previously 
published and 25 still unpublished patients with a pathogenic germline 
SUFU mutation were compiled.  RESULTS: 124 patients in 67 fam-
ilies were identified, most of them ascertained after the occurrence of a 
medulloblastoma (MB) or as part of Gorlin syndrome cohorts. Overall, 30 
patients were healthy carriers and 94 patients developed a total of 129 tu-
mors (up to 4 tumors/patient): 68 MBs, always as first tumor (median age 
at diagnosis: 1.5yr [0.1–5]), 22 patients with at least 1 basal cell carcinoma 
(BCC) (median 10/patient) (median age at first BCC: 43yr, [17–52]), 15 
meningiomas (median age 43yr, [13–72]), 7 ovarian stromal/fibrous tumors 
(median age 12yr [5–34]), and 17 other tumors including 5 sarcomas (me-
dian age: 50yr [7–79]). Median age at last follow-up was 30yr. Nineteen 
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